While antibodies currently play a dominant role as affinity reagents in biological research and for diagnostics, a broad range of recombinant proteins are emerging as promising alternative affinity reagents in detection assays and quantification. DNA-mediated affinity-based assays, such as immuno-PCR and proximity ligation assays (PLA), use oligonucleotides attached to affinity reagents as reporter molecules. Conjugation of oligonucleotides to affinity reagents generally employs chemistries that target primary amines or cysteines. Because of the random nature of these processes neither the number of oligonucleotides conjugated per molecule nor their sites of attachment can be accurately controlled for affinity reagents with several available amines and cysteines. Here, we present a straightforward and convenient approach to functionalize recombinant affinity reagents for PLA by expressing the reagents as fusion partners with SNAP protein tags. This allowed us to conjugate oligonucleotides in a site-specific fashion, yielding precisely one oligonucleotide per affinity reagent. We demonstrate this method using designed ankyrin repeat proteins (DARPins) recognizing the tumor antigen HER2 and we apply the conjugates in different assay formats. We also show that SNAP or CLIP tags, expressed as fusion partners of transfected genes, allow oligonucleotide conjugations to be performed in fixed cells, with no need for specific affinity reagents. The approach is used to demonstrate induced interactions between the fusion proteins FKBP and FRB by allowing the in situ conjugated oligonucleotides to direct the production of templates for localized rolling circle amplification reactions.
Introduction
For biomedical research and diagnostics, there is a need for standardized high-performance assays to analyze proteins and their interactions and modifications in situ, in cell lysates, or in body fluids. Such assays are likely to play increasing roles in medical practice by revealing diagnostic protein patterns, and supporting the selection of optimal therapy. These applications will require high-performance protein assays and broadly available repertoires of well-characterized affinity reagents for proteins of interest [1] .
Currently, polyclonal or monoclonal antibodies are used in most affinity-based protein analyses, but several classes of recombinant affinity reagents are under development such as nanobodies [2] , affibody [3] , DARPins and others [4] [5] [6] . Such reagents can offer important advantages in terms of engineered specificity and affinity, and also in production. Because of properties such as excellent stability, small size and the possibility to engineer them for convenient application in specific assay formats, they can extend the range of applications of affinity reactions beyond those of antibodies. Examples of recombinant affinity reagents include molecules that represent fragments of antibodies and a range of scaffold proteins designed to exhibit contact surfaces that can be varied for binding to putative target proteins [4, 5] . A scaffold protein with attractive properties for high-affinity protein binding is the designed ankyrin repeat proteins (DARPins) [6] . These are approximately 15-20 kDa in size (compared to 150 kDa for intact IgG antibodies) and they exhibit impressive stability, surviving for months at 378C. Because the DARPins have no cysteines and fold well in the cytoplasm, they can also be expressed within the cell. A repertoire of DARPins directed against extracellular and intracellular target proteins is now available [6] , and a particular effort has been devoted to generating DARPins against the ErbB receptor family, with affinities in the low nM to pM range [7] [8] [9] .
Proximity ligation assay (PLA) can provide improved opportunities for measuring proteins [10] or more complex targets such as interacting or aggregated proteins [11] and exosomes [12] in blood samples and cell lysates [13] . The technique can also be applied to visualize endogenous protein interactions [14] [15] [16] and post-translational modifications [17] in cells and tissues. Detection of proteins or protein complexes using PLA requires binding by two or more affinity reagents that are equipped with DNA oligonucleotides, and referred to as PLA probes. Upon proximal binding by a set of PLA probes amplifiable DNA strands, representative of proximal binding events, are formed by DNA ligation. The reaction provides high selectivity due to the requirement for multiple recognitions and good sensitivity of detection is ensured via amplified detection. For localized detection using in situ PLA, the DNA strands (priming and non-priming) coupled to affinity reagents serve first as templates for ligation, creating circular DNA molecules and then the priming acts as primer for localized amplification via rolling circle amplification (RCA) to form RCA products, containing hundreds copies of the same oligonucleotide sequence. The RCA products are easily detected as bright fluorescent spots using fluorophore-labeled hybridization probes (Fig. 1A) . These spots can then be digitally recorded using dedicated software [18] . Real-time PCR is generally used to measure ligation products representing proteins detected in solution phase such as in cell lysates (Fig. 1B) .
The first demonstration of PLA reactions made use of DNA aptamers as affinity reagents for the targeted proteins [10] , but in subsequent work poly-or monoclonal antibodies have generally been used. Several different chemistries are available to conjugate DNA strands to proteins. For antibodies, random coupling of oligonucleotides to primary amines is most commonly used [11, 13, 19] . Conjugation of oligonucleotides to larger affinity reagents is relatively straightforward, but the process is poorly defined and target binding may be affected. It is therefore desirable to conjugate oligonucleotides in a site-directed fashion and preferably in a one-to-one ratio. For small proteins, where a significant fraction of the surface is potentially involved in binding to the target, random coupling of oligonucleotides is unsuitable. For DARPins, protocols have been reported for stoichiometric sitespecific coupling of ligands such as polyethylene glycol (PEG) and fluorophore at the N-terminal amino group, at engineered cysteines or at modified amino acids capable of undergoing click chemistry [20] . These reactions require purification of the ligand (here an oligonucleotide) and the protein, as well as some considerations about buffer and reaction conditions. For highthroughput protein-oligonucleotide couplings, alternative strategies with lower demands on reagent purity are thus of interest. A mutant form of the human DNA repair protein O 6 -alkylguanine-DNA alkyltransferase reacts rapidly and specifically with O 6 -benzylguanine (BG) and also with derivatives that carry a large moiety linked to the benzyl group [21] . With guanine as the leaving group, the benzyl moiety becomes covalently attached to a cysteine in the active site of the enzyme. The enzyme has also been mutagenized to become specific for O 6 -benzylcytosine (BC) in a similar manner [22] . Both enzyme domains (about 20 kDa) are commercially available as SNAP and CLIP tags, respectively [22] [23] [24] .
Here we have investigated the coupling of BG-modified DNA oligonucleotides to DARPin-SNAP fusion proteins. Using anti-HER2 DARPins [7] [8] [9] as a test case the resulting PLA probes were validated by visualizing expression and interactions of endogenous HER2 proteins in cells, and by measuring HER2 levels in cell lysates. Furthermore, we illustrated the possibility to demonstrate protein interactions in situ using BG-and BC-modified DNA oligonucleotides as probes for in situ PLA detection of SNAP or CLIP fusion proteins, expressed in transfected cells. The transfected cells were fixed and permeabilized and interactions were analyzed by adding BG-and BC-modified DNA oligonucleotides as PLA probes. The oligonucleotides coupled in situ guided the circularization of two other DNA strands that were then amplified by RCA and visualized via hybridization of fluorophore-labeled oligonucleotides. We show that this form of in situ PLA could successfully demonstrate induced interactions between FKBP and FRB proteins fused to SNAP-and CLIP-domains, respectively, with no need for specific affinity reagents.
Materials and methods
Cloning, expression and purification of DARPin-SNAP fusion proteins
The ORFs for the anti-HER2 DARPins 9.01 [8] and G3 [7] were digested with BamHI and HindIII (New England Biolabs, Ipswich, MA) and ligated into the compatible expression vectors pQiBi_11_S-NAP or pQiBi_SNAP_11, which had been constructed by inserting the SNAP domain into vectors made for creating DARPin fusion proteins [9] (C. Gehringer et al., unpublished). This encodes DARPins N-or C-terminally fused to the SNAP-tag via an (G 4 S) 2 linker. Fusion proteins were overexpressed in Escherichia coli XL1-Blue and purified via their N-terminal MRGSH 6 tag with nickelnitrilotriacetic acid superflow resin (Qiagen, Hilden, Germany) giving yields of 25-40 mg of purified protein per liter expression culture [7, 8] .
Plasmid construction of FKBP-SNAP and FRB-CLIP gene fusion constructs
Gene construct encoding a fusion protein of FKBP (FK506-binding protein) and the SNAP-tag, or construct encoding a fusion protein of FRB (FKBP12/rapamycin-binding domain) and the CLIP-tag were each cloned in a pNuc vectors as previously described [25] , hereafter, referred to as FKBP-SNAP and FRB-CLIP. To identify transfected cells, a GFP-encoding vector, the pLPS-AcGFP1-N vector (Cat. No. 632472; Clontech), was co-transfected with the FKBP-SNAP and FRB-CLIP gene fusion constructs.
Preparation of PLA probes 50 mL of 100 mM aldehyde-modified oligonucleotides (priming, nonpriming, biovic 1 and biovic 2, Table 1 ) were incubated for 3 hours at RESEARCH PAPER New Biotechnology Volume 30, Number 2 January 2013 378C with a 30-fold molar excess of BG-hydrazine (5 mM in dimethylformamide (DMF); Covalys, Switzerland) in conjugation buffer (100 mM MES, 150 mM NaCl, pH 4.8). The BG-modified oligonucleotides were purified by reverse-phase high-performance liquid chromatography (RP-HPLC) using a 4.6 mm Â 250 mm silica matrix column with a particle size of 5 mm (Lichrosphere RP18 column; Supelco. Inc.), a 60-min gradient of 2-60% B (A: 0.1 M triethylamine acetate (pH 7.0); B: acetonitrile) and a flow rate of 1 mL/min. The reactive cysteine in the SNAP-tag-DARPin fusion proteins (G3 and 9.01) were reduced in 20 mM DTT, and incubated overnight at 48C in 1 mM DTT with a 3-fold molar excess of BG-modified oligonucleotides, resulting in PLA probes G3-SNAP-priming, non-priming-SNAP-G3, priming-SNAP-9.01, biovic1-SNAP-G3 and biovic2-SNAP-9.01 (Table 2) . No purifications of the conjugates were undertaken, because remaining unconjugated oligonucleotides were removed by washes in the in situ and solid phase PLA reactions. The formation of conjugates was validated by separating the products in a SDS polyacrylamide gel (GeneGel Excel 12.5%; GE Healthcare), followed by protein silver staining (PlusOne TM silver staining kit; GE Healthcare) (Fig. 1A) , band intensities were measured using Image J and the conjugation efficiency was calculated via the intensity of the conjugate band divided by the intensity of the non-conjugated SNAP-DARPin band. The anti-HER2 antibody pertuzumab and the anti-HER2 polyclonal antibody (AF1129, R&D Systems) were conjugated separately with aldehyde-modified priming and non-priming oligonucleotides and with aldehyde-modified biovic 1 and biovic 2 oligonucleotides (Table 1) , respectively, as previously described [26] . In preparing probes for in situ analysis of FKBP and FRB interaction, 50 mL of 100 mM thiol-modified priming oligonucleotide was reduced in 20 mM DTT for 1 hour at 378C. The reduced oligonucleotide was purified by MicroSpin G-50 column (GE healthcare) and incubated for 2 hours at room temperature (RT) with a 30-fold molar excess of BC-maleimide, followed by RP-HPLC purification as described above. The preparation of nonpriming-BG was performed in the same way as for aldehyde-modified non-priming oligonucleotide (Table 2) .
Cell cultures
The HER2 expressing breast cancer cell line (SK-BR-3) and ovarian cancer cell line (SK-OV-3) were grown in RPMI1640 medium and the human embryonic kidney cell line HEK 293T was grown in Dulbecco's modified Eagle's medium (DMEM). All media were supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 1% penicillin-streptomycin (all reagents from Sigma Aldrich). The cells were grown at 378C in a humidified 5% CO 2 environment.
Detection of HER2 in cells by in situ PLA
10,000 cells were seeded per well and cultivated overnight on LabTek Chamber Slides (Nalge Nunc International). Cells fixed in EtOH were blocked in blocking buffer (1 mg/mL BSA, 20 mg/mL salmon sperm DNA, 2 mM cysteine, 0.05% Tween20 in TBS buffer) for 1 hour at 378C, followed by incubation with 40 mL of DARPin PLA probes (non-priming-SNAP-G3 (2.4 nM) + G3-SNAP-priming (2.4 nM), non-priming-SNAP-G3 (4.8 nM) + priming-SNAP-9.01 (23 nM), Table 2 ) diluted in blocking buffer ON at 48C. Circularization oligonucleotide 1 and 2 (125 nM each, Table 1 ) in ligation buffer (0.25 mg/mL BSA, T4 ligase buffer, 1 mM ATP, 250 mM NaCl, 0.05% Tween20, 0.05 U/mL T4 DNA ligase (Fermentas)) were incubated at 378C for 30 min. After ligation rolling circle amplification (RCA) was performed (0.25 mg/mL BSA, phi29 polymerase buffer, 0.25 mM dNTP, 0.125 U/mL phi29 polymerase (Thermo Scientific)) for 90 min at 37 8C followed by hybridization of 250 nM detection oligonucleotide (Table 1) in detection buffer (2 Â SSC, 0.25 mg/mL BSA, 75 ng/mL polyA, 0.05% Tween20) to the single-stranded RCA product for 30 min at 378C. All steps were separated by two washes in TBS + 0.05% Tween20 (TBST). The slides were counterstained with DAPI (100 mg/mL) in Vectashield mounting medium (Vector Laboratory). The same protocol was used for the pertuzumab PLA probe (10 nM of each probe).
Detection of HER2 in cell lysate by solid-phase PLA , AJ Roboscreen) were coated with pertuzumab (1 ng/mL) in carbonate buffer (50 mM Na 2 CO 3 , 50 mM NaHCO 3 , pH 9.6) for 1 hour at 378C. After blocking for 1 hour at 378C in PBS containing 1% BSA, 0.1% salmon sperm DNA and 0.05% Tween20, the tubes were incubated with 50 mL of cell lysate at 48C ON. Subsequently, 50 mL of DARPin PLA probes (2 nM, biovic1-SNAP-G3 and biovic2-SNAP-9.01) or anti-HER2 antibody PLA probes (1 nM) was added to the tubes and incubated for 1.5 hours at 378C. All steps were separated by three washes in PBS with 0.05% Tween20 (PBST). Thereafter, 50 mL ligation and PCR mix (PCR buffer (Invitrogen)), 100 nM connector oligonucleotide (Table 1) Table 1 ), 220 nM Taqman probe (Table 1) were added. The real-time PCR was performed in a Mx-3000 instrument (Stratagene), with an initial incubation at 958C for 2 min, followed by 45 cycles of 958C for 15 s and 608C for 1 min. Solid-phase PLA was also performed with lysate buffer alone as a negative control. The results are presented as threshold cycle (Ct) values [27] , reflecting the amount of PLA ligation products, and as DCt value where the Ct values for lysate buffer have been subtracted from the Ct value for the cell lysate.
Detection of FKBP and FRB interaction
FKBP-SNAP and FRB-CLIP fusion encoding plasmids were co-transfected together with a GFP-expressing vector and transiently New Biotechnology Volume 30, Number 2 January 2013 RESEARCH PAPER 0.1% DMSO was included as a control for the effect of DMSO on the FKBP/FRB interaction. Cells were then fixed in 3% paraformaldehyde (PFA) (Sigma-Aldrich) for 15 min at RT, permeabilized for 15 min in 0.1% Triton X-100 (Sigma-Aldrich) in PBS, and briefly washed in PBS. 20 nM of priming-BC and 20 nM non-priming-BG in PBS was applied to the cells and incubation for 1 hour at 378C was followed by 3Â 5 min washing in TBST. The in situ PLA was performed as described above by steps of hybridization of circularization oligonucleotides, RCA and detection.
Image analysis
Images of all cell experiments were taken in a Zeiss Axioplan II epifluorescence microscope, using an AxioCam MRm CCD sensor and a 40x/1.3 Oil PlanNeofluar objective together with filters for RESEARCH PAPER New Biotechnology Volume 30, Number 2 January 2013 Results and discussion Preparation of PLA probes using SNAP-and CLIP-tag technology and verification by in situ and solid-phase PLA Simple and efficient methods to attach DNA strands to recombinant affinity proteins are needed to functionalize the reagents for use in methods such as immuno-PCR and PLA [28] . Here, we demonstrate a straightforward approach to convert recombinant affinity reagents into PLA probes by using SNAP-tag fusions of DARPin affinity reagents for site-specific and stoichiometrically controlled conjugation of oligonucleotides. We wished to evaluate if the reactivity of the 20 kDa SNAP and CLIP tags, engineered to react covalently with benzyl-guanine or benzyl-cytosine derivatives, could be exploited to attach oligonucleotides to proteins. Two different approaches were used to obtain BG-(or BC-) derivatized oligonucleotides. Aldehyde-oligonucleotide was first coupled to hydrazine-BG and the product was purified via RP-HPLC. An analogous reaction was also carried out between thiolmodified oligonucleotide and the corresponding maleimide-BC derivative. The BG-coupled oligonucleotides were then incubated with DARPins fused to the SNAP domain tag, resulting in conjugates with a one-to-one ratio of oligonucleotides to affinity reagents. In this manner, 75-85% of total DARPin-SNAP-tag fusion proteins were successfully coupled to an oligonucleotide each, as exemplified by the DARPin PLA probe shown in Fig. 2A . Because the BG-and BC-modified oligonucleotides are stable for long periods they can be prepared in large batches, facilitating DNA conjugation to many SNAP-or CLIP-labeled reagents. Two DARPins were used in these studies that both recognize the extracellular part of the human HER2 membrane protein, frequently overexpressed in, for example, breast cancer [29] . G3 has a K D of about 100 pM to domain IV of HER2 [7, 9] , and 9.01 [8] binds domain I with a K D of about 80 nM (C. Jost et al., unpublished). Because it was not clear a priori whether the 20-kDa SNAP domain might interfere with binding by the DARPin to HER2 on the cell, constructs were prepared with the SNAP domain either at the N-or C-termini of the DARPins. All products were obtained from E. coli at the same high yield as unfused DARPins. The HER2-specific DARPin-SNAP conjugates (PLA probes) were applied for HER2 expression analyses both by in situ PLA (schematic illustration of in situ PLA in Fig. 1A) , and in solid-phase PLA of cell lysates with quantitative PCR readout (schematic illustration of solid-phase PLA in Fig. 1B) . When two different DARPins are used to bind different epitopes of HER2, then both mono-and dimeric HER2 can be detected, while with DARPins binding to the same epitope (conjugated to different oligonucleotides), only homo-dimeric or clustered forms of HER2 would be detected. With HER2-overexpressing SK-OV-3 cells, the signals obtained using two different DARPin-based PLA probes (referred to as non-priming-SNAP-G3 and priming-SNAP-9.01) or only one DARPin (non-priming-SNAP-G3 and G3-SNAP-priming) are about the same. This suggests that most of the HER2 proteins are in a clustered state on this cell line (Fig. 2B,C) . Clustering of highly overexpressed HER2 on tumor cells is consistent with previous observations [30] . Using pairs of PLA probes based on the therapeutic monoclonal antibody pertuzumab, similar results were obtained (Fig. 2B,C) . By contrast, HEK 293T cells are known to express low but still measurable amounts of HER2 [31] . In these cells, HER2 is not expected to be oligomeric. Indeed, PLA signals were only seen when two different DARPins were used (Fig. 2B,C ), but not with only one DARPin or with pertuzumab.
The DARPin-SNAP PLA probes were also applied for protein measurements in cell lysates by solid-phase PLA with quantitative PCR readout. Here, HER2 levels in cell lysates from HER2 expressing SK-BR-3 cells and low HER2-expressing HEK 293T cells were compared. HER2 proteins were captured by pertuzumab immobilized on solid support and assayed using either two different DARPin PLA probes, one binding to domain IV (biovic1-SNAP-G3) and the other binding to domain I (biovic2-SNAP-9.01), or an anti-HER2 polyclonal antibody divided in two aliquots, each conjugated to one of two different oligonucleotides. Both experiments revealed the expected difference in levels of HER2 proteins between the two lysates (Fig. 3) . It should be pointed out that the two DARPins used both recognize conformational epitopes, and thus lysate preparations that even partially denature HER2 risk decreasing assay sensitivity. The polyclonal anti-HER2 antibody (AF1129, RnD systems) that was used in this assay, together with pertuzumab as capture antibody on solid support, has been shown to detect HER2 in Western blots and must thus be able to detect denatured forms of HER2, or unfolded regions. The polyclonal antibody might simultaneously bind different epitopes of HER2 and there may be several oligonucleotides attached per antibody. By contrast, the DARPins are monoclonal and strictly contain only one oligonucleotide each, and will therefore produce less signals overall than the antibody-based assay, both for lysates from SK-BR-3 cells expressing high levels of HER2 and from HEK 293T cells (Fig. 3A) . The differences in HER2 detection signals between SK-BR-3 and HEK 293T cells were similar, however, using the two classes of affinity reagents (DCts of 6.4 and 6.7, for DARPins and antibodies respectively) (Fig. 3B) .
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In situ conjugation of SNAP-and CLIP-fusion proteins
At times it is desirable to measure binding to and interactions among proteins for which no suitable affinity reagents exist. We investigated the possibility of transfecting cells with SNAP-and CLIP-fusion gene constructs to study protein interactions with no need for antibodies or any other specific protein-binding reagents. We tested this strategy using FKBP and FRP as model system, as interaction between these proteins can be induced by rapamycin. Rapamycin binds with high affinity (K D = 0.2 nM) to the 12-kDa FK506 binding protein (FKBP) as well as to a 100-amino acid domain of the mammalian target of rapamycin (mTOR), known as the FKBP-rapamycin binding domain (FRB), thereby forming a FKBPÁrapamycinÁFRB ternary complex [32, 33] . In cells transfected with SNAP-and CLIP-domains fused to FKBP and FRB proteins, respectively, the fusion proteins were conjugated in situ with BG-and BC-modified DNA oligonucleotides. Colocalization of the two oligonucleotides was investigated, by addition of two connector oligonucleotides, capable of being ligated into a DNA circle in reactions templated by the BG-and BC-oligonucleotides. We demonstrated successfully circularized oligonucleotides via RCA, followed by detection of the amplification products using fluorophore-labeled oligonucleotides, complementary to the repeated sequence of the RCA products. In the absence of rapamycin, the transfected HEK 293T cells, expressing FKBP-SNAP and FRB-CLIP, gave rise to only very few in situ PLA reaction products (1-10 RCPs per cell) (Fig. 4A) , whereas upon incubation with 20 mM rapamycin the numbers of signals per cell increased to greater than 100 per cell (Fig. 4B,C) .
This approach provides a way to use in situ PLA where proteins of interest can be expressed as fusion proteins with the SNAP or CLIP domains after transfection. This strategy could also be combined with the use of specific affinity reagents in situation where such a reagent is only available against one partner in a protein interaction. The procedure, which works on cells that have been fixed and permeabilized, provides a complementary method to in situ interaction analysis of genetically modified living cells via Förster resonance energy transfer (FRET) of pairs of fluorescent protein domains that are expressed as fusions to the proteins of interest [34, 35] or by using complementing protein domains on fusion proteins [36] . Although the in situ PLA approach, unlike FRET and protein complementation techniques, is limited to fixed cells, the strong signal amplification can be of value because it enables detection of individual interaction events using standard microscopy.
Conclusion
Because the reaction of BG-or BC-modified oligonucleotides with SNAP or CLIP tags is a robust and specific procedure, this strategy will be helpful to functionalize a large range of recombinant affinity reagents for proteomics investigation through the addition of DNA strands. It thus provides a general means for production of highly stable, renewable DNA-conjugated affinity reagents with one oligonucleotide added in a site-specific fashion per affinity reagent molecule. This was demonstrated for HER2-specific DARPin PLA probes. We also demonstrate that BG-and BCmodified oligonucleotides can be used as general affinity reagents directly in cells transfected with fusion gene constructs.
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